Tabid, Dan Aiza .
HRN: 20-46-76 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/12/2023
CEFUROXIME 750MG (VIAL)
05/12/2023
05/18/2023
IVT
500 Mg
Q8
Urti
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaURTI Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes